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Background: Benign familial neonatal seizures are most often
caused by mutations in the voltage-gated potassium channel
subunit gene KCNQ2. More than 60 mutations have been
described in BFNS families, approximately half of which lead to
protein truncation. The hypothesis of this study was that deletion
or duplication of >1 exons of KCNQ2 could cause BFNS in
cases without coding or splicing mutations.
Methods: Multiplex ligation-dependent probe amplification
(MLPA) was used to test a group of 21 unrelated patients with
clinical features consistent with either BFNS, benign familial
neonatal–infantile seizures or sporadic neonatal seizures, for
exonic deletions and duplications.
Results: Three deletions and one duplication mutation were
identified in four familial cases and cascade testing of their
available family members showed that the mutations segre-
gated with the phenotype in each family. The junction fragment
for one of the deletions was amplified by PCR and sequenced to
characterise the breakpoint and verify that a deletion had
occurred.
Conclusions: Submicroscopic deletions or duplications of
KCNQ2 are seen in a significant proportion of BFNS families:
four of nine (44%) cases previously testing negative for coding
or splice site mutation by sequencing KCNQ2 and KCNQ3.
MLPA is an efficient second-tier testing strategy for KCNQ2 to
identify pathogenic intragenic mutations not detectable by
conventional DNA sequencing methods.
B
enign familial neonatal seizures (BFNS; OMIM 121200)
and benign familial neonatal–infantile seizures (BFNIS;
OMIM 607745) are autosomal dominant seizure disorders
of early infancy. In BFNS, affected neonates have onset of
seizures in the first few days of life and offset usually occurs by
a few months of age.1 BFNS is caused in most families by
mutations in the voltage-gated potassium channel subunit
genes KCNQ2 (OMIM 602235) and KCNQ3 (OMIM 602232),2–4
and to date, .60 mutations in these genes have been reported
in BFNS families. Most of these mutations are in KCNQ2.5 6 In
contrast, the age of seizure onset in BFNIS varies from the
neonatal period to 13 months of age.7 BFNIS, which is caused
by mutations of the voltage-gated sodium channel subunit gene
SCN2A (OMIM 182390), is rarer than BFNS, with 11 families
described to date.7–10 Although there is phenotypic overlap
between these two disorders, they can be diagnosed on clinical
grounds but with the probability of correct diagnosis increasing
with the number of affected family members for whom the age
of seizure onset is accurately known.
Approximately half of the KCNQ2 mutations described in
BFNS are truncations, splice site defects, or deletions or
insertions of a small number of bases causing frameshifts. All
these are predicted to lead to haploinsufficiency, as no
functional protein can be produced from the mutated allele.
Larger deletions and duplications affecting >1 exons of KCNQ2
would also be predicted to cause BFNS. The chance finding of a
submicroscopic deletion that removed an allele of a micro-
satellite marker closely linked to KCNQ2, causing apparent
aberrant segregation, was originally exploited to identify
KCNQ2 as a BFNS gene.4 This deletion was later found to
remove the last nine exons of the KCNQ2 gene and 22 kb of the
39 genomic sequence.11 However, no other mutations altering
the copy number of >1 contiguous exons have subsequently
been described because this type of mutation is not detectable
using standard, systematic PCR-based mutation screening and
sequencing methods.
The development of multiplex ligation-dependent probe
amplification (MLPA) allows the relatively rapid and inexpen-
sive screening of patients for deletions, duplications and other
copy number variants affecting any number of contiguous
exons in a selected gene by testing for changes in the copy
number of each exon.12 We used this technology to screen for
intragenic copy number variations in KCNQ2 in a group of
unrelated patients in whom KCNQ2 and KCNQ3 mutations had
been previously excluded by direct sequencing.
METHODS
Patients and DNA samples
In total, 21 probands were tested, of whom 18 had neonatal
seizures. Of these 18 probands, 8 had classic BFNS, 7 had
sporadic neonatal seizures and 3 had familial neonatal seizures
with atypical features such as refractory ongoing epilepsy and
developmental delay. The patients with neonatal seizures had
previously been tested by direct sequencing for mutations in all
coding exons of KCNQ2 and exons 5 and 6 of KCNQ3. Three
probands were from families diagnosed with BFNIS and these
patients had also been sequenced for all coding exons of SCN2A.
The initial clinical diagnosis of BFNS versus BFNIS in families
with both neonatal and early infantile onset (less than
6 months) was determined as follows. Where the majority of
cases had a neonatal onset and a single case or small number of
cases had early infantile onset, BFNS was diagnosed. Where
early infantile and neonatal onset were in similar proportions,
or early infantile predominated, a clinical diagnosis of BFNIS
was made. DNA was extracted from peripheral blood samples
using standard methods. The study was approved by the ethics
committee of Austin Health.
Multiplex ligation-dependent probe amplification
Samples were prepared for MLPA by repurifying 1 mg of DNA
using the Qiaquick PCR purification kit (Qiagen, Valencia,
California, USA). MLPA was carried out using the SALSA
Abbreviations: BFNIS, benign familial neonatal-infantile seizures; BFNS,
benign familial neonatal seizures; MLPA, multiplex ligation-dependent
probe amplification; OMIM, Online Mendelian Inheritance in Man
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MLPA kit P166 KCNQ2 (MRC Holland, Amsterdam, The
Netherlands) according to the manufacturer’s instructions.
This kit contains probes specific for 14 of 17 exons and the
promoter of KCNQ2 (probes for exons 2, 8 and 14 are not
included) and 13 control probes specific for other regions of the
human genome. Automated analysis, using GeneMarker V.1.5
software (SoftGenetics, State College, Pennsylvania, USA)
comparing peak heights was carried out on files directly
imported from an ABI 3100 Avant DNA analyser (Applied
Biosystems, Foster City, California, USA).
Long-range PCR and sequencing of products
Long-range PCR to search for amplifiable junction fragments
was carried out using Platinum Taq High Fidelity DNA
Polymerase (InvitrogenCarlsbad, California, USA). PCRs were
set up and run according to the manufacturer’s instructions.
Reactions contained between 40 ng and 100 ng of template
DNA. The reactions were cycled for 35 cycles with an extension
time of 4 minutes and a 5-minute final extension following
cycling. Products were separated by electrophoresis on 0.8%
agarose gels and visualised by ethidium bromide staining.
Figure 1 Scatter plots generated from the
analysis of MLPA data using GeneMarker
software. The five panels show the results for
a control sample and a member of each of
the four families (respectively: A:II:4; B:II:2;
C:II:5; D:III:4) with deletions or duplications
involving KCNQ2. The points represent the
comparative peak height ratios for each
probe in the MLPA kit compared with normal
samples, as calculated by GeneMarker
software. A ratio ,0.75 indicates a deletion
and .1.25 indicates a duplication of the
exon; these thresholds are indicated by the
parallel solid lines on each plot. The light
grey points within the normal range
represent results for KCNQ2 probes and the
dark grey points within the normal range are
results for control probes specific to other
regions of the human genome.
Figure 2 Genomic structure of KCNQ2 and
the regions affected by the deletion or
duplication in each family.
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Products for sequencing were purified using the Qiaquick PCR
purification kit (Qiagen). Sequencing reactions were carried out
using BigDye V. 3.1 (Applied Biosystems) and analysed on an
ABI 3730 capillary sequencer (Applied Biosystems).
RESULTS
Three deletions and a duplication were identified in 4 of the 21
patients tested (fig 1). Of the 14 unsolved familial cases,
deletions or duplication mutations involving multiple exons
occurred in 3 classic BFNS families and 1 initially suspected on
clinical grounds of being BFNIS. No mutations were present in
the remaining seven sporadic cases of neonatal seizures.
The three deletions detected all removed multiple contiguous
exons of KCNQ2: in family A, exons 3–11 were deleted; in family
B, exons 13–15; and in family D exons 1–5. The duplication in
family C involved an extra copy of exons 3–12, inserted in
unknown orientation (fig 2). All available relatives of these
patients were tested by MLPA. The respective deletions were
detected in nine affected members in family A and all four
affected members and one obligate carrier (D-III-2) in family D.
The deletion in family B was detected in both affected members
but was not seen in either of the unaffected members of the
first generation of this family and therefore represents a de
novo mutation. Segregation of 12 highly polymorphic micro-
satellite markers was consistent with the pedigree as given.
Four affected members of family C were tested, and the
duplication was present in all of them. The pedigrees of the four
families are shown in figure 3.
Of the four families with mutations, two (B and C) were
typical BFNS families on clinical grounds. Family D was
initially ascertained with one confirmed neonatal onset and
one definite infantile onset case and was tentatively diagnosed
as BFNIS; subsequently, two more relatives with neonatal onset
were ascertained. This, and the molecular result showing the
Figure 3 Pedigrees of the four families with
KCNQ2 MLPA detected microchromosomal
abnormalities.
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deletion of KCNQ2 exons 1–5, led to the definitive diagnosis as
BFNS. Family A has eight members who had neonatal seizures
with onset of seizures in the first month of life. Seizures were
focal clonic or generalised tonic–clonic with apnoea and all
ceased by 12 months of age. An additional three family
members (A:II:4, A:III:4 and A:III:5) had seizures commencing
in adulthood. Two members had focal seizures that secondarily
generalised, while the third had several nocturnal tonic–clonic
seizures that could not be classified. None of these three
members experienced seizures in the neonatal period (although
the mother of A:II:4 was not available for questioning). The
clinical details of the affected members of the four families are
summarised in table 1.
As there were no prior samples with KCNQ2 deletions
available to validate the MLPA procedure, we chose one case
to independently confirm the result. LR-PCR was carried out to
characterise the breakpoints of the smallest deletion, which
was in family B. The primers 59-GCTTCCTCTCTGAAGTGT
GTCAG-39 and 59-TACTGCAGGAGAGACTCTCAACAG-39 were
used to amplify a product spanning both deletion breakpoints
for the deletion that excised exons 13–15. The expected normal
PCR product from these primers is 3849 bp in length. This
product was not successfully amplified; however, a smaller
product of approximately 800 bp in length was amplified from
the homologue affected by the deletion from two affected
members of family B (fig 4A). This confirmed the presence of
the deletion detected by MLPA and indicated that the size of
the deletion in family B was approximately 3 kb. The product
amplified from individual B:II:2 was sequenced to determine
the exact excision points for the deletion, the exact size of the
deletion and if additional nucleotides were incorporated during
the DNA repair that rejoined the sequence (fig 4B). The deletion
in family B was IVS12-768 to IVS15+572 del3018bp, effectively
validating the MLPA result. No additional nucleotides were
added to the sequence during DNA repair. The exact size of the
PCR product was 831 bp.
DISCUSSION
The occurrence of submicroscopic deletions and duplications at
the intragenic level of resolution was predicted for KCNQ2,
based on the high proportion of known truncating mutations in
the gene. MLPA was used to screen a group of families
Table 1 Clinical details of affected family members
Patient
ID Sex Age Onset Offset Clinical features
A:II:1 M 61 years Neonate 12 months
A:II:4 F 58 years 37 years 50 years Neonatal history not known. Five nocturnal
seizures
A:III:1 M 34 years 7 days 10 months Four seizures
A:III:2 M 31 years ,1 month ,12 months Ten seizures
A:III:3 F 29 years 3 days 6 months
A:III:4 M 37 years 26 years 30 years No neonatal seizures. Six PSSG in 6 weeks
A:III:5 M 36 years 20 years Not known No neonatal seizures. Six PSSG
A:IV:1 M Not known 9 days 9 days
A:IV:3 M 7 months 4 days 5 days Single cluster of 8 seizures
B:II:2 F 32 years 2 days 2 days Two seizures
B:III:1 F 7 months 2 days 9 days Nine seizures occurring in three clusters
C:I:2 F 57 years Neonatal ,4 months
C:II:1 F 40 years 4 months Ongoing Cluster of seizures occurring every 1–2 hours
over 2–3 days. PSSG in adolescence and
adulthood
C:II:5 F 37 years 10 months 10 months Single seizure during febrile illness
C:III:11 M 15 years 7 days 7 days Single cluster of seizures
C:III:12 F 3 years 5 days 3 years Five clusters over 4 months. Further seizures
when unwell
D:II:2 F 55 years 5 days 12 years Tonic–clonic seizures
D:III:4 F 27 years 4 months 4 months Single cluster of 4 seizures
D:IV:3 M 1.5 years 5 days 4 months Nine seizures occurring in four clusters
D:IV:4 M 2 months 5 days 5 days Single cluster of 5 seizures
PSSG, partial seizure secondarily generalised.
Figure 4 Amplification and
characterisation of the breakpoint in family
B. (A) 0.8% agarose gel of LR-PCR products
from four members of family B and a
negative (water) control. The markers used
on this gel were the GeneRuler 1 kb DNA
ladder (Fermentas). (B) Part of the
sequencing trace from the product amplified
from patient B:II:2, showing the deletion
breakpoint, indicated by the arrow.
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tentatively diagnosed on clinical grounds as BFNS or BFNIS,
and a group of patients with sporadic neonatal seizures, in
whom KCNQ2 mutations had not previously been identified by
PCR-based techniques. Submicroscopic deletions and a dupli-
cation mutation were detected in three of eight likely BFNS
families and one of three possible BFNIS families, definitively
diagnosing the latter as BFNS based on the molecular result
and bringing the total number of BFNS families in the study to
nine. The same mutations were detected in all affected relatives
of each proband. No mutations were detected in the sporadic
cases with neonatal seizures. The detection rate for deletions
and duplications in patients with BFNS who had previously
tested negative by sequencing for KCNQ2 and KCNQ3 mutations
was 44%.
For one mutation, the deletion breakpoints were charac-
terised. The DNA repair in this case was not accompanied by
nucleotide insertions. A 4 bp nucleotide insertion was pre-
viously characterised as part of the DNA repair process
associated with an SCN1A deletion detected by MLPA.13 Few
such breakpoints have been characterised.
All four mutations detected are very likely to be pathogenic,
causing the loss of one functional copy of the KCNQ2 gene, and
therefore haploinsufficiency. This mechanism has been sug-
gested for BFNS2 and is the likely result of the numerous
truncating mutations of KCNQ2 identified in BFNS families.
The KCNQ2 protein forms part of the inhibitory M-channel and
therefore reduction in its activity, resulting from either
missense mutations or haploinsufficiency, is expected to
increase neuronal excitability and therefore seizure suscept-
ibility.
Two families (C and D) each contained a single person who
had onset of seizures at 4 months of age. BFNS families with
KCNQ2 mutations have been reported in which occasional
members had seizure onset between 1 and 8 months of age.11
Family C has an extensive family history of seizures, all
commencing in the neonatal period, therefore the single
individual with later seizure onset did not modify our diagnosis
of BFNS (see Methods), but was considered to fall within this
previously observed variation. However, family D is much
smaller, initially with only two confirmed affected members.
One had neonatal onset and one had infantile onset, leading to
the initial diagnosis of BFNIS. This illustrates that the clinical
distinction between BFNS and BFNIS is difficult in small
families with both neonatal and infantile onsets. A family with
a KCNQ2 mutation has previously been reported in which the
onset of seizures occurred between 2 and 4 months of age,
consistent with a familial diagnosis of BFNIS.14 Together with
our data, this further highlights the phenotypic overlap
between families with KCNQ2 and SCN2A mutations and the
need to incorporate genetic testing as part of the patient
investigation if a definitive clinicomolecular syndromal diag-
nosis is required. Detection of the KCNQ2 defect in family D and
the ascertainment of two more affected members with neonatal
seizure onset suggested that the diagnosis of BFNS for the
family is more likely.
Family A has two members who did not have observed
neonatal seizures, confirmed by a reliable maternal history, but
did have focal seizures commencing in adulthood. Their mother
also had seizures in adult life, but her neonatal history was
unknown. These three people (A:II:4, A:III:4 and A:III:5) all
have the BFNS-related KCNQ2 intragenic deletion. The muta-
tion may be responsible, at least in part, for the partial epilepsy
in these members as an alternative phenotype.
Other than the families included in this study, we have
examined 15 BFNS families in whom missense or truncating
mutations were previously detected by sequencing (Biervert et
al2, Richards et al 15 and unpublished data). Submicroscopic
deletions or duplications were detected in four of the nine
BFNS families that were studied here by MLPA, bringing the
total number of BFNS families for whom we have identified
mutations to 19 out of a total of 24 studied. These numbers
suggest that submicroscopic deletions and duplications in
KCNQ2 account for a significant proportion of unsolved familial
cases in which mutations are not detected by direct sequencing:
over one-fifth of all KCNQ2 mutations and one-sixth of BFNS
families.
A small proportion of probable BFNS families remains
unsolved. These could be caused by pathogenic mutations in
the promoter or introns of KCNQ2, or additional genetic
heterogeneity. The promoter and most of the intronic sequences
are not usually covered by PCR-based mutation screens, but
mutations in these regions could lead to downregulation of
transcription or incorrect splicing of the KCNQ2 transcript.
There may also be deletions or promoter mutations in KCNQ3,
although mutations leading to haploinsufficiency are less likely
in KCNQ3 given that all the mutations described to date in this
gene are missense mutations.5 Another possibility is the
presence of at least one other BFNS gene, the existence of
which is likely to be confirmed only if a family is identified that
is large enough for exclusion of linkage to both KCNQ2 and
KCNQ3 or by demonstration of linkage to another region of the
genome. A final possibility is that a proportion of cases could be
polygenic, which might include large copy number variations
affecting a number of susceptibility genes related to channel
function or expression, including KCNQ2 and KCNQ3.
These results suggest that MLPA is an important second-tier
testing strategy for suspected cases of BFNS or BFNIS without
previously identified KCNQ2, KCNQ3 or SCN2A coding or splice-
site mutations. Submicroscopic deletions and duplications of
KCNQ2 may account for a significant proportion of these cases.
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